Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Ambrx Inc." found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Ambrx Inc. for you to read. Along with our medical data and news we also list Ambrx Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Ambrx Inc. Companies for you to search.
Cris Calsada joins the biopharma from Ambrx
Tracon Pharmaceuticals Inc. granted Ambrx Inc. exclusive rights to develop and sell the endoglin antibody TRC105 (carotuximab...
Deals and Financings Nanjing Legend Biotech received a very large $350 million upfront payment from Janssen Biotech to partner Legend's impressively effective CAR-T candidate; Crown Bioscience, a CRO with facilities in China and elsewhere, will be acquired for $400 million by Japan's JSR, double its previous valuation; JHL Biotech is planning a voluntary delisting from the Taiwan stock exch...
Ambrx announced a $143.5 million agreement to in-license China rights for a liver cancer treatment with an anti-angiogenesis mechanism, developed by Tracon Pharma of San Diego. Two years ago, Ambrx, a San Diego-Shanghai antibody-conjugate biotech company, was acquired by Fosun Pharma (SHA: 600196; HK: 02196) and WuXi PharmaTech plus two China equity investors. The new agreement gives Ambrx rights ...
The transaction grants Ambrx the exclusive rights to develop and commercialize TRC105 in all indications (excluding ophthalmology, which are held by Santen Pharmaceutical Co., Ltd.) Read more...
The partnership resolves around the commercialization and development of TRC105 (carotuximab) in China
Initial Focus in China on Angiosarcoma and Hepatocellular Carcinoma Total Value of Deal up to $143.5 Million for TRACON, Including
TRACON will receive an upfront payment of $3M, and is eligible to receive development and regulatory milestones of up to $10.5M, and commercial sales milestones of up to $130M.
SummaryAmbrx Inc Ambrx is a biopharmaceutical company which focuses on the discovery and development of proteinbased medicines by using its expanded genetic code. The company's pipeline product candidate's portfolio includes ARX618 FGF21, PSMA ADC, CD70 ADC and AntiCD3 X Folate. It develops pipeline candidates for various therapeutic indications such as diabetes, oncology and heart failure. Ambrx ...
TP Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focusing on addressing oncology drug resistance, announced the appointment of Sheila K. Gujrathi MD to the Company’s Board of Directors and as a strategic advisor. “The Board and I are extremely delighted to have Dr. Sheila Gujrathi join us as director and strate...